Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca's Saphnelo (anifrolumab) autoinjector pen wins FDA approval for systemic lupus erythematosus based on Ph3 results
Antibody, autoimmune, monoclonal antibody, systemic lupus erythematosus, type I interferon receptor, subcutaneous administration - Read more

Novartis' Rhapsido (remibrutinib) receives European Commission approval as first oral BTK inhibitor for chronic spontaneous urticaria
Small molecule, autoimmune, BTK inhibitor, chronic spontaneous urticaria, histamine pathway - Read more

Crinetics Pharmaceuticals' PALSONIFY (paltusotine) receives European Commission approval for acromegaly in adults following Ph3 trials
Small molecule, metabolic, somatostatin receptor agonist, acromegaly, endocrine disorder - Read more

UK MHRA grants marketing authorisation to MSD's Enflonsia for RSV prevention in infants
Monoclonal antibody, infectious disease, regulatory, competitive - Read more

Teikoku Seiyaku, Curedisc sign license agreement for KTP-001 lumbar disc herniation treatment in Japan
Licensing deal, musculoskeletal, recombinant protein, regulatory, commercialization - Read more

HK inno.N, Atomatrix partner to develop AI-driven small molecule non-incretin obesity treatments
Co-development, small molecule, obesity, AI/ML, drug discovery - Read more

Thermo Fisher Scientific divests microbiology business to Astorg for $1.075B
Divestiture, diagnostics, infectious disease, manufacturing, equity investment - Read more

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

Mundipharma, CorMedix's Rezzayo (rezafungin) meets Ph3 endpoint for invasive fungal disease prevention in allogeneic hematopoietic stem cell transplant patients
Small molecule, infectious disease, antifungal, invasive fungal disease, hematopoietic stem cell transplant - Read more

Oruka Therapeutics' ORKA-001 (orka-001) shows Ph2 promise in plaque psoriasis, achieving total skin clearance in nearly two-thirds of patients
Antibody, autoimmune, monoclonal antibody, psoriasis, IL-23 inhibitor, long-acting therapy - Read more

Veradermics' VDPHL01 (minoxidil) hits Ph3 goal in male pattern baldness, first potential new pill in 30 years
Small molecule, dermatological, oral formulation, male pattern baldness, minoxidil, hair loss - Read more

Intellia Therapeutics' lonvo-z succeeds in Ph3 trial for hereditary angioedema, company begins rolling FDA submission
Gene therapy, rare disease, CRISPR, hereditary angioedema, gene editing - Read more

Keythera Pharmaceuticals' KF-0210 (EP4 receptor antagonist) cuts pain scores 86.7% in Ph2a knee osteoarthritis study
Small molecule, musculoskeletal, EP4 receptor antagonist, osteoarthritis, pain management - Read more

Cantargia's nadunolimab (IL1RAP) shows early Ph1b/2a complete remissions in high-risk myelodysplastic syndrome and acute myelogenous leukemia
Antibody, cancer, monoclonal antibody, myelodysplastic syndrome, acute myeloid leukemia, IL1RAP - Read more

Rejuvenate Bio launches crowdfunding campaign to advance gene therapy for aging, chronic diseases
Gene therapy, aging, chronic disease, preclinical - Read more

Hemab plans $180M IPO to advance clotting disorder pipeline, including sutacimig
Rare disease, antibody, hematology, clinical-stage - Read more

Fathom Therapeutics raises $47M Series A for quantum chemistry and AI-driven small molecule drug design
AI/ML platform, small molecule, drug discovery, platform-enabled - Read more

Veradermics plans public offering of 3.35M shares for pattern hair loss therapies
Dermatology, hair loss, small molecule, clinical-stage - Read more

Seaport plans $180M IPO to fund depression candidate SPT-300 advancement
Neurological, small molecule, platform technology, depression, clinical-stage - Read more

Pfizer settles with Dexcel, Cipla in Vyndamax patent dispute, potentially delaying generic ATTR-CM competition
Small molecule, cardiovascular, competitive, financial - Read more

UK biotech VC funding rises 17% in Q1 2026, showing recovery signs, but IPO activity remains stagnant
Venture capital, biotech funding, financial, strategic - Read more

Ligand Pharmaceuticals to acquire Xoma Royalty for $739M, nearly doubling its royalty aggregator portfolio
Royalty aggregation, rare disease, major transaction, strategic - Read more

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, expanding oncology portfolio with next-gen JAK2 inhibitor
Small molecule, oncology, rare disease, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Compass Therapeutics' (tovecimig) Ph2/3 overall survival data raise approvability concerns for biliary tract cancer
Antibody, cancer, bispecific antibody, biliary tract cancer, PD-1, combination therapy - Read more

Astellas relies on five strategic brands to offset projected Xtandi decline in fiscal 2026
Small molecule, oncology, strategic, revenue impact, competitive - Read more

FDA criticizes Incyte over misleading promotional claims for cGVHD drug Niktimvo
Monoclonal antibody, rare disease, regulatory, competitive - Read more

FDA issues warning letters to UCSF, Par Health over environmental monitoring failures
Radiopharmaceutical, sterile injectable, regulatory, operational, manufacturing compliance - Read more

Astellas halts (resamirigene bilparvovec) gene therapy, pivots to ASP2957 Ph1/2 for X-linked myotubular myopathy
Gene therapy, rare disease, small molecule, X-linked myotubular myopathy, AAV capsid, autoimmune - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here